PK and Tolerability of CKD-348 Co-administered with CKD-828, D097, and D337 in Healthy Volunteers

Phase 1, randomised, open-label trial of telmisartan, Levamlodipine, rosuvastatin and ezetimibe in hypertension (HTN) and dyslipidemia (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area under the concentration-time curve from time zero to the last measurable concentration at 72 hours and Maximum observed plasma concentration at 72 hours. Started Sep 2022; status: completed.